J Korean Ophthalmol Soc.  2016 Nov;57(11):1684-1690. 10.3341/jkos.2016.57.11.1684.

Surgical Outcomes of Dacryocystorhinostomy in Lacrimal Drainage Obstruction after Systemic Chemotherapy or Radioactive Iodine Therapy

• Kim DG
• Lee JJ
• Ham DS
• Yang JW

• KMID: 2357722
• DOI: http://doi.org/10.3341/jkos.2016.57.11.1684

Abstract

PURPOSE
To compare the outcomes of endonasal dacryocystorhinostomy in patients with secondary lacrimal drainage obstruction associated with systemic chemotherapy or radioactive iodine therapy.
METHODS
We retrospectively reviewed the clinical records of patients diagnosed with secondary lacrimal drainage obstruction after systemic chemotherapy or radioactive iodine therapy for thyroid disease and surgical treatment by endonasal dacryocystorhinostomy between January 2009 and January 2015. The control group included randomly selected patients who underwent endonasal dacryocystorhinostomy after diagnosis of primary lacrimal drainage obstruction.
RESULTS
Patients were separated into a chemotherapy group (13 eyes of 9 patients), a radioactive iodine therapy group (44 eyes of 32 patients), and a control group (50 eyes of 40 patients). Duration from the onset of systemic chemotherapy or radioactive iodine to the first epiphora symptom was shorter in the chemotherapy group than the radioactive iodine therapy group (p < 0.001). There was no significant difference between the three groups in success rate of endonasal dacryocystorhinostomy.
CONCLUSIONS
Most patients with secondary lacrimal drainage obstruction associated with systemic chemotherapy or radioactive iodine therapy had successful outcome of endonasal dacryocystorhinostomy. The success rate of dacryocystorhinostomy was comparable to that in patients with primary lacrimal drainage obstruction.

Keyword

Chemotherapy; Dacryocystorhinostomy; Radioactive iodine; Secondary lacrimal drainage obstruction

MeSH Terms

Dacryocystorhinostomy*
Diagnosis
Drainage*
Drug Therapy*
Humans
Iodine*
Lacrimal Apparatus Diseases
Retrospective Studies
Thyroid Diseases
Iodine

Reference

References

1. Bartley GB. Acquired lacrimal drainage obstruction: an etiologic classification system, case reports, and a review of the literature. Part 3. Ophthal Plast Reconstr Surg. 1993; 9:11–26.

2. Esmaeli B, Hidaji L, Adinin RB, et al. Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy. Cancer. 2003; 98:504–7.

3. Pakdel F, Bahmani Kashkouli M. Lacrimal drainage obstruction associated with topical and systemic medications. J Ophthalmic Vis Res. 2009; 4:270–1.

4. McCartney E, Valluri S, Rushing D, Burgett R. Upper and lower system nasolacrimal duct stenosis secondary to paclitaxel. Ophthal Plast Reconstr Surg. 2007; 23:170–1.

5. Kim N, Park C, Park DJ, et al. Lacrimal drainage obstruction in gastric cancer patients receiving S-1 chemotherapy. Ann Oncol. 2012; 23:2065–71.

6. El-Sawy T, Ali R, Nasser QJ, Esmaeli B. Outcomes of abdominal in patients with head and neck cancer treated with high-dose radiation therapy. Ophthal Plast Reconstr Surg. 2012; 28:196–8.

7. Park JH, Jung SK, Paik JS, Yang SW. Outcomes of endoscopic abdominal in patients receiving radioactive iodine abdominal for thyroid carcinoma. J Korean Ophthalmol Soc. 2014; 55:333–6.

8. Munk PL, Lin DT, Morris DC. Epiphora: treatment by means of dacryocystoplasty with balloon dilation of the nasolacrimal abdominal apparatus. Radiology. 1990; 177:687–90.

9. Hazin R, Abuzetun JY, Daoud YJ, Abu-Khalaf MM. Ocular abdominals of cancer therapy: a primer for the ophthalmologist abdominal cancer patients. Curr Opin Ophthalmol. 2009; 20:308–17.

10. Imperia PS, Lazarus HM, Lass JH. Ocular complications of abdominalic cancer chemotherapy. Surv Ophthalmol. 1989; 34:209–30.

11. Brink HM, Beex LV. Punctal and canalicular stenosis associated with systemic fluorouracil therapy. Report of five cases and review of the literature. Doc Ophthalmol. 1995; 90:1–6.

12. Bartley GB. Acquired lacrimal drainage obstruction: an etiologic classification system, case reports, and a review of the literature. Part 2. Ophthal Plast Reconstr Surg. 1992; 8:243–9.

13. Eiseman AS, Flanagan JC, Brooks AB, et al. Ocular surface, ocular adnexal, and lacrimal complications associated with the use of abdominalic 5-fluorouracil. Ophthal Plast Reconstr Surg. 2003; 19:216–24.

14. Esmaeli B, Valero V, Ahmadi MA, Booser D. Canalicular stenosis secondary to docetaxel (taxotere): a newly recognized side effect. Ophthalmology. 2001; 108:994–5.

15. Chan A, Su C, de Boer RH, Gajdatsy A. Prevalence of excessive tearing in women with early breast cancer receiving adjuvant doce-taxel-based chemotherapy. J Clin Oncol. 2013; 31:2123–7.

16. Kintzel PE, Michaud LB, Lange MK. Docetaxel-associated epiphora. Pharmacotherapy. 2006; 26:853–67.

17. Esmaeli B, Amin S, Valero V, et al. Prospective study of incidence and severity of epiphora and canalicular stenosis in patients with metastatic breast cancer receiving docetaxel. J Clin Oncol. 2006; 24:3619–22.

18. Tsalic M, Gilboa M, Visel B, et al. Epiphora (excessive tearing) and other ocular manifestations related to weekly docetaxel: abdominal dose-limiting toxicity. Med Oncol. 2006; 23:57–61.

19. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005; 352:2302–13.

20. Shirasaka T. Development history and concept of an oral abdominal agent S-1 (TS-1): its clinical usefulness and future vistas. Jpn J Clin Oncol. 2009; 39:2–15.

21. Esmaeli B, Golio D, Lubecki L, Ajani J. Canalicular and abdominal duct blockage: an ocular side effect associated with the antineoplastic drug S-1. Am J Ophthalmol. 2005; 140:325–7.

22. Leyssens B, Wildiers H, Lobelle JP, et al. A double-blind abdominal phase II study on the efficacy of topical eye treatment in the prevention of docetaxel-induced dacryostenosis. Ann Oncol. 2010; 21:419–23.

23. Morgenstern KE, Vadysirisack DD, Zhang Z, et al. Expression of sodium iodide symporter in the lacrimal drainage system: abdominal for the mechanism underlying nasolacrimal duct abdominal in I(131)-treated patients. Ophthal Plast Reconstr Surg. 2005; 21:337–44.

24. Shepler TR, Sherman SI, Faustina MM, et al. Nasolacrimal duct obstruction associated with radioactive iodine therapy for thyroid carcinoma. Ophthal Plast Reconstr Surg. 2003; 19:479–81.

25. Bakheet SM, Hammami MM, Hemidan A, et al. Radioiodine abdominal in tears. J Nucl Med. 1998; 39:1452–4.

26. Kloos RT, Duvuuri V, Jhiang SM, et al. Nasolacrimal drainage abdominal obstruction from radioactive iodine therapy for thyroid carcinoma. J Clin Endocrinol Metab. 2002; 87:5817–20.

27. Burns JA, Morgenstern KE, Cahill KV, et al. Nasolacrimal abdominal secondary to I(131) therapy. Ophthal Plast Reconstr Surg. 2004; 20:126–9.

28. Fonseca FL, Lunardelli P, Matayoshi S. Lacrimal drainage system obstruction associated to radioactive iodine therapy for thyroid carcinoma. Arq Bras Oftalmol. 2012; 75:97–100.

29. Al-Qahtani KH, Al Asiri M, Tunio MA, et al. Nasolacrimal duct obstruction following radioactive iodine 131 therapy in abdominaliated thyroid cancers: review of 19 cases. Clin Ophthalmol. 2014; 8:2479–84.

30. Hwang MW, Lee E, Yang JW. Nasolacrimal duct obstruction after radioactive iodine therapy for thyroid cancer. J Korean Ophthalmol Soc. 2014; 55:1–6.